Telix Reports the Completion of Patient Enrollment in P-III (ZIRCON) Study of TLX250-CDx for the Treatment of Clear Cell Renal Cell Cancer
Shots:
- The company has dosed the final patient & completed enrollment in the P-III (ZIRCON) study to evaluate the sensitivity & specificity of TLX250-CDx (89Zr-DFO-girentuximab) in 252 patients with ccRCC at 34 sites in EU, Australia, Turkey, Canada & the US. The results are expected in H2’22
- If the study is successful, TLX250-CDx might offer a non-invasive method for ccRCC diagnosis & staging along with detection of metastatic disease through whole-body imaging resulting in improved patient management by reducing the need for surgical intervention
- According to Telix's compassionate use policy & national regulatory procedures, TLX250-CDx will be made available to qualifying patients under EAP in selected countries
Ref: PRNewswire | Image: Telix Pharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
